THE ROLE OF CFDNA CONCENTRATION IN VARIOUS CARDIAC DISEASES AND IT’S CORRELATION WITH COVENTIONAL BIOMARKERS
Md. Sakibur Rahman Tapu, Gong Kaizheng*, Yao Deshan, Yuan Mengxuan and Guo Jiao Jiao
Objective: To quantify the concentration of plasma cfdna in patients with cardiovascular diseases and healthy volunteers at different stages, analyze the correlationship between plasma cfdna and traditional biomarkers with clinicopathological features of cardiovascular patients. Additionally, evaluate its significance in early clinical diagnosis of cardiac disease state. In recent years cell free DNA’s are coming under spotlight while establishing it’s significance in the field of precision medicine. Over the past decades it has been affirmed that larger amount of cell free DNA’s can be detected in the circulation with pathological condition which plays a significant role suggesting a noteworthy clinical part in cancer, Diabetes mellitus, Rheumatoid Arthritis, prenatal screening, inflammation, stroke, myocardial infarction and variety of cardiac diseases. Method: We purified cfDNA directly from peripheral blood using magnetic beads by modifying binding and lysis conditions followed by a spectrometric Dna concentration test. Result : The serum from cardiac patients showed significant cfDNA elevation (p<0.01). The interquartile value of cfDNA (median 136.79 μg/ml, range 10.54–263.04 μg/ml), (median 36.62 μg/ml, range 17.58-57.67μg/ml), (median 8.18μg/ml range 1.83-14.53μg/ml), (median 12.65 μg/ml range 4.67-20.63μg/ml) account respectively for Myocardial infarction, Cardiac angina, Atrial fibrillation, and cardiac failure vs. (median 5.46 μg/ml, range 1.38–9.54 μg/ml) indicating healthy controls patients were shown. In our study we didn’t find any significant correlation of cfDNA concentration with CRP and CK-MB respectively even though noteworthy elevation of cfDNA was observed in selected cardiac patients. Conclusion: These results enlighten us to brief that plasma cfDNA in cardiac patients may originate from apoptosis and suggest a impactful diagnostic validity.
Keywords: cfDNA, MI, biomarkers, CVD.
[Full Text Article]